Literature DB >> 1828396

Inhibition of T suppressor cell function by local administration of an active cyclophosphamide derivative at the sensitization site.

J Limpens1, R J Scheper.   

Abstract

In previous work, we have shown that local administration of active cyclophosphamide (CY) derivatives, or other cytostatic drugs, at the sensitization site induced a similar immunopotentiation to that of systemic CY. Since it is well documented that CY can inhibit suppressor cells, it was proposed that immunoenhancement by locally administered drugs might be based on a similar principle. The objective of the present study was to test this hypothesis, using an experimental model of Ts mediated suppression of delayed type hypersensitivity to sheep erythrocytes. In this model, mice are made tolerant to sheep erythrocytes by i.v. injection of a high dose of sheep erythrocytes. Local treatment of sheep erythrocytes-tolerant mice with the active CY derivative Z7557 at the site of attempted sensitization reversed suppression in a dose-dependent manner. Local treatment with the cytostatic drug etoposide (VP-16) and systemic CY treatment were also effective. In transfer experiments, the function of afferently acting suppressor cells was blocked by local treatment with Z7557 or systemic CY. These data support the concept of anti-suppressor cell activity of locally administered cytostatic drugs. As with CY, the pharmacological basis of this effect remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828396      PMCID: PMC1535431     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  Synergistic effects of locally administered cytostatic drugs and a surfactant on the development of delayed-type hypersensitivity to keyhole limpet haemocyanin in mice.

Authors:  J Limpens; R J Scheper
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

2.  Break of unresponsiveness of delayed-type hypersensitivity to sheep red blood cells by pertussis toxin.

Authors:  S Tamura; H Tanaka; R Takayama; H Sato; Y Sato; N Uchida
Journal:  Cell Immunol       Date:  1985-05       Impact factor: 4.868

Review 3.  The MOPC-315 tumor as a model for the immunomodulatory effects of cyclophosphamide.

Authors:  M B Mokyr
Journal:  Methods Find Exp Clin Pharmacol       Date:  1987-09

4.  In vitro effects of 4-hydroperoxycyclophosphamide on concanavalin A-induced human suppressor T cells.

Authors:  A Klajman; I Drucker; Y Manor; S Ben-Efraim
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma.

Authors:  D M Sahasrabudhe; J B deKernion; J E Pontes; D M Ryan; R W O'Donnell; D M Marquis; G S Mudholkar; C S McCune
Journal:  J Biol Response Mod       Date:  1986-12

6.  Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma.

Authors:  P O Livingston; S Cunningham-Rundles; G Marfleet; C Gnecco; G Y Wong; G Schiffman; W E Enker; M K Hoffman
Journal:  J Biol Response Mod       Date:  1987-08

7.  Inhibition of suppressor T lymphocytes (Ts) by cimetidine.

Authors:  D M Sahasrabudhe; C S McCune; R W O'Donnell; E C Henshaw
Journal:  J Immunol       Date:  1987-05-01       Impact factor: 5.422

8.  In vitro effects of 4-hydroxyperoxycyclophosphamide on human immunoregulatory T subset function.

Authors:  J J Smith; E Mihich; H Ozer
Journal:  Methods Find Exp Clin Pharmacol       Date:  1987-09

9.  Local administration of cytostatic drug 4-hydroperoxy-cyclophosphamide (4-HPCY) facilitates cell-mediated immune reactions.

Authors:  G H Boerrigter; R J Scheper
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

10.  Tumor regression and induction of anti-tumor immunity by local chemotherapy of guinea-pigs bearing a line-10 hepatocarcinoma.

Authors:  A M Claessen; H Valster; H Bril; P A Steerenberg; B T Tan; R J Scheper
Journal:  Int J Cancer       Date:  1991-02-20       Impact factor: 7.396

View more
  1 in total

1.  Advanced ovarian cancer: Vaccination site draining lymph node as target of immuno-modulative adjuvants in autologous cancer vaccine.

Authors:  Eduardo Lasalvia-Prisco; Emilio Garcia-Giralt; Silvia Cucchi; Jesús Vázquez; Leonard Robinson; John Dalton
Journal:  Biologics       Date:  2007-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.